INS and type 1 diabetes mellitus: The “Diabetes Prediction and Prevention Study” (DIPP) trial was performed in a population with a genetic predisposition for developing T1D and positivity for at least two autoantibodies through intranasal insulin administration; however, this trial was stopped due to a lack of benefit, even though the safety of intranasal insulin was demonstrated [69,70].